Colon and rectal cancer combined are the fourth most commonly diagnosed cancers. Eighty percent of patients are diagnosed at a stage of disease when treatment is given with curative-intent. However, treatment can have both short- and long-term side effects that may impact quality of life. To address these concerns, investigators at Dana-Farber have led clinical … Read more
As a cancer imaging fellow at Dana-Farber, Michael Rosenthal, MD, PhD, spent about two years working on a radiologist’s version of paint-by-number. Together with his colleagues, he annotated 687 computed tomography (CT) scans, manually differentiating skeletal muscle from fat tissue by labelling them with different colors. The work was part of a 2018 project to … Read more
Wind up a mechanical mouse, set it down, and watch it go. New research by Dana-Farber scientists shows that boosting a single protein in the liver can have the same animating effect in real mice. The protein, called MIC19, produces changes deep inside liver cells that help the body burn nutrients, protecting against obesity and … Read more
There are several ways to ruin a tune: play the wrong notes, play them at the wrong time, or with the wrong emphasis. Cancer cells, working from a corrupted score – their genome – manage to do all three. In cancer, bad instructions meet improper execution. Tumor cells are notorious for alterations of their genome: … Read more
Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse. Dana-Farber researcher Patrick Bhola, PhD, calls these cells “bad actors.” They are up to no good. In a new paper, he describes a technique to identify potential bad actors before treatment … Read more
Artificial Intelligence (AI) has tremendous potential to advance healthcare and improve the lives of everyone. But successful clinical translation requires evaluating the performance of AI models on large and diverse real-world datasets. MLCommons, an open global engineering consortium dedicated to making machine learning better for everyone, announced on July 17, 2023, a major milestone toward … Read more
As science and clinical medicine advance, oncologists increasingly face the challenge of information overload. It can be hard for oncologists, especially those in community practices who cover many cancers, to keep up with the influx of new therapies, biomarkers, and clinical trial results. The go-to solution has been the systematic review. Researchers team up to … Read more
In early March of 2018, at age 58, Roger Miller went to a local doctor’s office in Maine for outpatient surgery. He’d been putting off getting what he’d thought was a cyst removed from the back of his head. During the procedure, he overheard the surgeon say, “Oh, this doesn’t look good.” Miller, who at … Read more
Animals — from oysters and corals to flies and mammals — encode proteins to sense their environment and share a common strategy to rally a defense. Scientists have identified a new family of immune proteins conserved across animal evolution with common features. Recent research from Dana-Farber Cancer Institute has added a new family to the … Read more
Like a mill crumbling into a river, solid tumors constantly shed bits of themselves — including their DNA — into the bloodstream. This free-floating genetic material, known as circulating tumor DNA, or ctDNA, contains a trove of information about the tumor. Advances in technology have made it possible to extract ctDNA from a blood sample, … Read more
For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options. Most patients with inoperable tumors would receive chemotherapy, usually a combination of fluorouracil, oxaliplatin and leucovorin (known as FOLFOX). While this regimen is often effective, patients eventually develop resistance to the treatment and their tumors progress. Now, the … Read more
In a branch of the PI3K protein family — with members named PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ — PI3Kβ was long treated as the proverbial middle child: neglected by cancer scientists in favor of its more prominent siblings. In a new study, Dana-Farber researchers demonstrate that it doesn’t deserve its obscurity — that in fact … Read more
When the time came for Jeffrey Ferreira to undergo a stem cell transplant for acute myeloid leukemia (AML), his Dana-Farber hematologist, Corey Cutler, MD, MPH, had some intriguing news: he was eligible for a clinical trial of a new approach to lowering the risk of chronic graft-versus-host disease (GVHD), a common and sometimes severe aftereffect … Read more
When scientists named microglial cells after the Greek word for “glue,” they thought it conveyed all one needed to know about the cells. The cells’ role, it was believed, began and ended with providing connective tissue for neurons, the information carriers of the nervous system. Research over many years has shown that moniker to … Read more
On a wave of promising research and positive media stories, psychedelic drugs are edging closer to mainstream use for treating a variety of mental disorders. A clinical trial recently launched by Dana-Farber investigators is the first to evaluate such an agent in patients receiving hospice care. The trial, which plans to enroll 15 patients served … Read more
When researchers report the survival effect of a cancer drug in a clinical trial, they almost always use a measure called hazard ratio. For all its ubiquity, however, hazard ratio has a hazard of its own: it’s a bit tricky to understand. A 2019 study found that 47% of researchers misinterpreted hazard ratio (HR) when … Read more
For nearly a century, scientists have appreciated that cancer cells rely on a process called glycolysis to grow and divide at very high rates. In the process, the cells avidly break down glucose to produce lactate, which has been considered a passive by-product — a mechanism known as the Warburg Effect, named after the German … Read more
A novel hematopoietic stem cell transplantation (HSCT) method utilizing ‘graft sculpting’ is being tested in a phase 1 clinical trial in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are at the highest risk of relapse after ‘standard’ transplants. In fact, the patients in the trial don’t qualify for a standard … Read more
Waldenström’s macroglobulinemia (WM) is a blood cancer that is extremely rare, affecting around 1500 people in the US each year. About 20 percent of those cases are considered familial, meaning that many members of the same family also have some form of blood cancer, such as myeloma or lymphoma. An even smaller group — five … Read more
Even as an infant is learning to distinguish herself from the rest of the world, a key part of her immune system is working toward the same goal, albeit in a very different manner. From before birth through the early years of life, young immune system cells in the thymus gland are receiving an education … Read more